Company Description
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.
It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs.
It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 4, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Raymond Tesi |
Contact Details
Address: 225 NE Mizner Blvd., Suite 640 Boca Raton, Florida 33432 United States | |
| Phone | 858 964 3720 |
| Website | inmunebio.com |
Stock Details
| Ticker Symbol | INMB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001711754 |
| CUSIP Number | 45782T105 |
| ISIN Number | US45782T1051 |
| Employer ID | 47-5205835 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raymond Joseph Tesi M.D. | Co-Founder, President, Chief Executive Officer, Chief Medical Officer and Chairman |
| David J. Moss M.B.A. | Chief Financial Officer, Treasurer and Secretary |
| Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Chief Scientific Officer and Chief Manufacturing Officer |
| Joshua S. Schoonover Esq. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 10, 2025 | SCHEDULE 13G/A | Filing |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 424B5 | Filing |